Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track

Protara Therapeutics, Inc.

2024-Q3 EPS reported -$1.74

Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.
Cash, equivalents, and investments $81.5M as of Sept 30; sufficient to fund operations into 2026.
R&D expenses $8.1M; G&A $4.3M; stock-based comp $0.9M.
On track to report interim 6-month data from TARA-002 in NMIBC ADVANCED-2 trial in 4Q 2024.
FDA Fast Track granted for IV Choline Chloride; THRIVE-3 first patient dosing expected in 1Q 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.